Skip to content

A retrospective cohort study on transcutaneous electrical acupoint stimulation for moderate to severe cancer pain in liver cancer

Transcutaneous electrical acupoint stimulation for the treatment of moderate to severe cancer pain in patients with liver cancer: a multicenter, bidirectional cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025002275
Enrollment
Unknown
Registered
2025-11-21
Start date
2025-11-30
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Interventions

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients who meet the diagnostic criteria for HCC; (2) The patient's age should be between 18 and 80 years old, with no gender restrictions. (3) The NRS score is =4, and there is persistent pain; (4) The Child Pugh score is A or B; (5) There is liver cancer-related pain, located in the right costal region or below the xiphoid process; (6) Expected survival period of more than 3 months; (7) The patient is conscious and capable of estimating their own pain, quality of life, etc. (8) Received at least one transcutaneous acupoint electrical stimulation treatment from November 2021 to December 2023; There are complete pain assessment, treatment records and follow-up data.

Exclusion criteria

Exclusion criteria: (1) Key information (such as cancer pain score, treatment parameters, survival outcome, etc.) is missing in medical records; (2) Other malignant tumors that may significantly affect the assessment of cancer pain or the treatment outcome; (3) Patients who were transferred to other hospitals halfway, lost to follow-up and had a follow-up period of less than one month.

Design outcomes

Primary

MeasureTime frame
NRS score for liver pain;

Secondary

MeasureTime frame
BPI-Q3 Q4 Q5 ;Dosage of analgesics;Frequency of gastrointestinal side effects of opioids;Comprehensive quality of life assessment, including the Karnofsky Performance Status (KPS) scale, the Quality of Life Scale for Liver Cancer (QOL-LC), and the Brief Fatigue Inventory (BFI) score.;Serum TRPA1, tumor necrosis factor-a (TNF-a), 5-hydroxytryptamine (5-HT), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-1ß (IL-1ß);

Countries

China

Contacts

Public Contactlijing

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

LIJINGacu@126.com18930568565

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026